CPP
NKTR icon

Crow Point Partners’s Nektar Therapeutics NKTR Stock Holding History

Crow Point Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9
Closed -$14K – 203
2018
Q1 		$14K Sell
9
-27
-75% -$34.8K ﹤0.01% 249
2017
Q4 		$33K Buy
+36
New +$21.3K 0.01% 231

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crow Point Partners's NKTR Position: Q2 2018 in Review

Crow Point Partners sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 9 shares — an estimated $14K sold.

Crow Point Partners first reported a position in NKTR in Q4 2017 and held it in 2 quarters. The position peaked at $33K in Q4 2017. 378 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Crow Point Partners reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Crow Point Partners sold 9 Nektar Therapeutics shares in Q2 2018, an estimated $14K.
  • Crow Point Partners first reported a position in Nektar Therapeutics in Q4 2017 and held it in 2 quarters.
  • Crow Point Partners's Nektar Therapeutics position peaked at $33K in Q4 2017.
  • 378 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Crow Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.